5414x -

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year.

: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas. : £72

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments : £72.1 million

The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights: : £72

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25

: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards.